menu search

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Leqembi® intravenous infusion (lecanemab) approved for the treatment of alzheimer’s disease in japan

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...

September 25, 2023, 5:02 am

Eisai presents latest analysis of lecanemab’s effect on biomarker changes and subcutaneous dosing at the alzheimer’s association international conference (aaic) 2023

Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying patho...

July 19, 2023, 11:30 pm

Eisai to present the latest alzheimer's disease pipeline and research, including lecanemab and anti-mtbr tau antibody e2814, at the alzheimer's association international conference (aaic) 2023

TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the...

July 11, 2023, 7:30 pm

Fda advisory committee votes unanimously to confirm the clinical benefit of leqembi® (lecanemab-irmb) for the treatment of alzheimer’s disease

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in...

June 9, 2023, 10:45 pm

Additional detailed analyses from phase 2 study 201 of lecanemab published as three papers in peer-reviewed journals

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...

March 30, 2023, 11:30 pm

Eisai presented new analyses of aria and qol on lecanemab in clarity ad at the ad/pd™ 2023 annual meeting

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...

March 30, 2023, 11:30 pm

Fda accepts eisai’s filing of a supplemental biologics license application and grants priority review for traditional approval of leqembi™ (lecanemab-irmb) for the treatment of alzheimer’s disease

Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approva...

March 5, 2023, 11:30 pm

Approval for anavex's blarcamesine looks inevitable after biogen's leqembi approved

FDA grants emergency approval of Biogen/Eisai's Leqembi (previously lecanemab), based solely on Phase 2...

January 30, 2023, 12:13 pm

lecanemab receives priority review status in japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (N...

January 29, 2023, 11:30 pm

Marketing authorization application for lecanemab as treatment for early alzheimer’s disease accepted by european medicines agency

TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (N...

January 26, 2023, 11:30 pm

Biogen (biib) partner eisai seeks nod for lecanemab in japan

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating ea...

January 16, 2023, 2:18 pm

Biogen's (biib) partner eisai files maa for lecanemab in europe

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for ...

January 11, 2023, 11:17 am

‘there is a lot that's underestimated at biogen': ceo viehbacher

Shares of Biogen Inc (NASDAQ: BIIB) have gained nearly 45% since late September but CEO Christopher Viehbacher says there's still “a lot that's unde...

January 9, 2023, 11:35 am

Fda approves eisai and biogen's new alzheimer's therapy

The Food and Drug Administration on Friday approved Eisai and Biogen's Alzheimer's treatment lecanemab,...

January 6, 2023, 2:37 pm

Fda approves alzheimer's drug that slowed cognitive decline in clinical trial

The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline ...

January 6, 2023, 2:11 pm

lecanemab alert: what would alzheimer's drug approval mean for biogen (biib) stock?

One stock that's trading in the right direction today is prominent mega-cap biotech stock Biogen (NASDAQ: BIIB ). Shares of BIIB stock have surged a...

January 6, 2023, 2:07 pm

Biogen could get a second alzheimer's ok — but will wild card medicare bite?

Biogen stock jumped Friday ahead of an FDA decision on the accelerated approval of its experimental Alzheimer's treatment, ...

January 6, 2023, 10:41 am

Amid criticism for its handling of another alzheimer's drug, fda will decide this week whether to approve lecanemab

The Food and Drug Administration is expected to make a decision on whether to approve a new Alzheimer's disease medication the week after a damning ne...

January 3, 2023, 2:47 pm


Search within

Pages Search Results: